• 1
    Burtness B, Anadkat M, Basti S et al. NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw 2009; 7 (Suppl 1): S5S21.
  • 2
    Shepherd FA, Rodrigues Pereira J et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123132.
  • 3
    Pérez-Soler R, Chachoua A, Hammond L et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 32383247.
  • 4
    Senderowicz A, Johnson J, Sridhara R et al. Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology 2007; 21: 16961709.
  • 5
    Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491500.
  • 6
    Segaert S, Chiritescu G, Lemmens L et al. Skin toxicities of targeted therapies. Eur J Cancer 2009; 45(Suppl 1): 295308.
  • 7
    Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 14251433.
  • 8
    Perez-Soler R, Delord JP, Halpern A et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005; 10: 345356.
  • 9
    Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6: 803812.
  • 10
    Fernandez-Torres R, Martinez Gomez W, Cuevas Santos J et al. Rosaceiform eruption induced by cetuximab. Eur J Dermatol 2010; 20: 392393.
  • 11
    Jacot W, Bessis D, Jorda E et al. Acniform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004; 151: 238241.
  • 12
    Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567578.
  • 13
    Boone SL, Rademaker A, Liu D et al. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 2007; 72: 152159.
  • 14
    Perez-Soler R, Saltz L. Cutaneous adverse events with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23: 52355246.
  • 15
    Lacouture ME, Lai SE. The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol 2006; 155: 852854.
  • 16
    Lynch TJ Jr, Kim ES, Eaby B et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007; 12: 610621.
  • 17
    Jatoi A, Nguyen PL. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist 2008; 13: 12011204.
  • 18
    Haley A, Calahan C, Gandhi M et al. Skin care management in cancer patients: an evaluation of quality of life and tolerability. Support Care Cancer 2011; 19: 545554.
  • 19
    Wacker B, Nagrani T, Weinberg J et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007; 13: 39123921.
  • 20
    Wolf M, Swaisland H, Averbuch S et al. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. Clin Cancer Res 2004; 10: 46074613.
  • 21
    Fluhr J, Miteva M, Primavera G et al. Functional assessment of a skin care system in patients on chemotherapy. Skin Pharmacol Physiol 2007; 20: 253259.
  • 22
    Ocvirk J, Cencelj S. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. J Eur Acad Dermatol Venereol 2010; 24: 453459.
  • 23
    Grenader T, Gipps M, Goldberg A et al. Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. Clin Lung Cancer 2008; 9: 5960.
  • 24
    Wolf R, Wolf D, Tüzün B et al. Soaps, Shampoos, Detergents. Clin Dermatol 2001; 19: 393397.
  • 25
    Skolarus T, Homes-Rovner M, Northouse L et al. Primary care perspectives on prostate cancer survivorship: Implications for improving quality of care. Urol Oncol 2011; Jul 18. [Epub ahead of print] PMID:21775171.
  • 26
    Health NIo. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4. [11 November 2011]; Available from:
  • 27
    Jatoi A, Green EM, Rowland KM Jr et al. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology 2009; 77: 120123.
  • 28
    Agero AL, Dusza SW, Benvenuto-Andrade C et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55: 657670.
  • 29
    Roe E, Garcia Muret MP, Marcuello E et al. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 2006; 55: 429437.
  • 30
    Ouwerkerk J, Boers-Doets C. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. Eur J Oncol Nurs 2010; 14: 337349.
  • 31
    Moore S. Managing treatment side effects in advanced breast cancer. Semin Oncol Nurs 2007; 23(4 Suppl 2): S23S30.
  • 32
    Galimont-Collen AF, Vos LE, Lavrijsen AP et al. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 2007; 43: 845851.
  • 33
    Hu JC, Sadeghi P, Pinter-Brown LC et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007; 56: 317326.
  • 34
    Wohlrab J, Luftner D, Johne A et al. The advantage of a proactive, barrier-protective, supportive skin care in patients with brest cancer on chemotherapy. Oncology 2011; 34: 62.
  • 35
    Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 16581664.
  • 36
    Bernier J, Bonner J, Vermorken J et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008; 19: 142149.
  • 37
    Rigopoulos D, Larios G, Gregoriou S et al. Acute and chronic paronychia. Am Fam Physician 2008; 77: 339346.
  • 38
    Joshi SS, Ortiz S, Witherspoon JN et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 2010; 116: 39163923.
  • 39
    Taggart L, Ozolins L, Hardie H et al. Look Good Feel Better Workshops: A “big lift” for women with cancer. J Cancer Educ 2009; 24: 9499.
  • 40
    Amiel P, Dauchy S, Bodin J et al. Evaluating beauty care provided by the hospital to women suffering from breast cancer. Support Care Cancer 2009; 17: 839845.
  • 41
    Titeca G, Poot F, Cassart D et al. Impact of cosmetic care on quality of life in breast cancer patients during chemotherapy and radiology. J Eur Acad Dermatol Venereol 2007; 21: 771776.
  • 42
    Anderson M, Johnson J. Restoration of body image and self-esteem fro women after concer treatment: a rehabiliatative survey. Cancer Pract 1994; 2: 345349.
  • 43
    Fawzy N, Secher L, Evans S et al. The Positive Appearance Center: an innovative concept in comprehensive psychosocial cancer care. Cancer Pract 1995; 3: 233238.
  • 44
    Hirsh V. Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol 2011; 18: 126138.
  • 45
    Williams S, Schreier A. The effect of education in managing side effects in women receiving chemotherapy for treatment of breast cancer. Oncol Nurs Forum 2004; 31: E16E23.
  • 46
    Thune P. The effects of Detergents on Hydration and Skin Surface Lipids. Clin Dermatol 1996; 14: 2933.
  • 47
    El-Abaseri T, Hansen L. EGFR activation and ultraviolet light-induced skin carcinogenesis. J Biomed Biotechnol 2007; 2007: 97939.
  • 48
    Jost M, Gasparro FP, Jensen PJ et al. Keratinocyte apoptosis induced by ultraviolet B radiation and CD95 ligation – differential protection through epidermal growth factor receptor activation and Bcl-x(L) expression. J Invest Dermatol 2001; 116: 860866.
  • 49
    Funke A, Kulp-Shorten C, Callen J et al. Subacute cutaneous lupus erythematosus exacerbated or induced by chemotherapy. Arch Dermatol 2010; 146: 11131116.
  • 50
    Luu MLS, Patel J, Guitart J et al. Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. Photodermatol Photoimmunol Photomed 2007; 23: 4245.
  • 51
    Battie C, Verschoore M. Dermatology, cosmetic and well being. Ann Dermatol Venerol 2001; 138: 294301.
  • 52
    Merial-Kieny C, Nocera T, Mery S et al. Medical corrective make-up in post chemotherapy. Ann Dermatol Venereol 2008; 1: 2528.